1. Scrip
  2. >>Focus On Asia
  3. >>Japan

MTP Building US Commercial Ops On Edaravone

 
• By Ian Haydock

Japanese mid-sized firm Mitsubishi Tanabe Pharma is building up its independent US commercial operations with a view to conducting the in-house marketing of new products, starting with an ALS therapy.

Mitsubishi Tanabe Pharma Corp. (MTP) has set up a new wholly owned subsidiary in the US to conduct in-house sales, marketing and medical affairs functions, with a view to starting independent sales of a new product for amyotrophic lateral sclerosis (ALS).

MT Pharma America Inc, based in Jersey City, New Jersey, is structured as a wholly owned subsidiary of Osaka-based MTP's US holding entity, which in turn is 100% held by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Japan Market Entry: Consortium’s One-Stop Shop To Support Foreign Entrants

 
• By Lisa Takagi

Japanese CDMO Bushu talks about a consortium designed to provide a broad range of development services to smaller foreign firms looking to bring high-need drugs to the Japanese market.

More from Focus On Asia

Pharma Women’s Workforce In India: Weak Start, Promotions, C-Suite Drop Off

 
• By Anju Ghangurde

McKinsey senior partner Vivek Pandit talks to Scrip about some of the intricacies underlying the key findings of a study on pharma’s workforce gender gap in India. Women’s representation starts low at entry level, peaks at senior manager positions and falls off again for C-suite roles, this found.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.